Oncorus®, Inc., to Present at the 29th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass., Nov. 14, 2017 /PRNewswire/ -- Oncorus^®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme, today announced that its Chief Executive Officer and co-founder, Mitchell H. Finer, PhD, will present a company overview at the 29^th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 3:30pm Eastern Time. The event will be held in New York at the Lotte New York Palace.

About Oncorus, Inc.
Oncorus, Inc., is a biotechnology company developing a portfolio of next-generation immunotherapy products, leveraging its proprietary oncolytic Herpes viruses platform, to treat several types of cancer, including highly malignant and aggressive cancers, based upon the work of renowned scientists Joseph Glorioso III, Ph.D., and Paola Grandi, Ph.D., from the University of Pittsburgh. A leader in corporate philanthropy, Oncorus has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. The company is located in Kendall Square, Cambridge, Massachusetts. Visit www.oncorus.com for more information.

SOURCE Oncorus, Inc.

Related Links

http://www.oncorus.com